Dexamethasone doses in patients with COVID-19 and hypoxia: A systematic review and meta-analysis.

Autor: Munch MW; Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.; Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark., Granholm A; Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.; Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark., Maláska J; Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.; Department of Simulation Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic.; 2nd Department of Anaesthesiology University Hospital Brno, Brno, Czech Republic., Stašek J; Department of Internal Medicine and Cardiology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Rodriguez PO; Pulmonary and Critical Care Medicine, Instituto Universitario CEMIC (Centro de Educación Médica e Investigación Clínica), Buenos Aires, Argentina., Pitre T; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Wilson R; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.; NIHR Applied Research Collaboration West (ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England., Savović J; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.; NIHR Applied Research Collaboration West (ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England., Rochwerg B; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Svobodnik A; Department of Pharmacology/CZECRIN, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Kratochvíl M; Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Taboada M; Department of Anaesthesiology and Intensive Care Medicine, Clinical University Hospital of Santiago, Sanitary Research Institute of Santiago (IDIS), Santiago, Spain., Jha V; The George Institute for Global Health, New Delhi, India.; School of Public Health, Imperial College, London, UK.; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India., Vijayaraghavan BKT; The George Institute for Global Health, New Delhi, India.; Department of Critical Care Medicine, Apollo Hospitals, Chennai, India., Myatra SN; Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Venkatesh B; The George Institute for Global Health, Sydney, New South Wales, Australia.; Department of Intensive Care Medicine, Wesley Hospital, Brisbane, Queensland, Australia.; University of Queensland, Brisbane, Queensland, Australia., Perner A; Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.; Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark., Møller MH; Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.; Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Acta anaesthesiologica Scandinavica [Acta Anaesthesiol Scand] 2024 Feb; Vol. 68 (2), pp. 146-166. Date of Electronic Publication: 2023 Oct 26.
DOI: 10.1111/aas.14346
Abstrakt: Background: The optimal dose of dexamethasone for severe/critical COVID-19 is uncertain. We compared higher versus standard doses of dexamethasone in adults with COVID-19 and hypoxia.
Methods: We searched PubMed and trial registers until 23 June 2023 for randomised clinical trials comparing higher (>6 mg) versus standard doses (6 mg) of dexamethasone in adults with COVID-19 and hypoxia. The primary outcome was mortality at 1 month. Secondary outcomes were mortality closest to 90 days; days alive without life support; and the occurrence of serious adverse events/reactions (SAEs/SARs) closest to 1 month. We assessed the risk of bias using the Cochrane RoB2 tool, risk of random errors using trial sequential analysis, and certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results: We included eight trials (2478 participants), of which four (1293 participants) had low risk of bias. Higher doses of dexamethasone probably resulted in little to no difference in mortality at 1 month (relative risk [RR] 0.97, 95% CI: 0.79-1.19), mortality closest to Day 90 (RR 1.01, 95% CI: 0.86-1.20), and SAEs/SARs (RR 1.00, 95% CI: 0.97-1.02). Higher doses of dexamethasone probably increased the number of days alive without invasive mechanical ventilation and circulatory support but had no effect on days alive without renal replacement therapy.
Conclusions: Based on low to moderate certainty evidence, higher versus standard doses of dexamethasone probably result in little to no difference in mortality, SAEs/SARs, and days alive without renal replacement therapy, but probably increase the number of days alive without invasive mechanical ventilation and circulatory support.
(© 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.)
Databáze: MEDLINE
Externí odkaz: